导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 0.03% | 2411/4773 |
| 近一周 | -1.33% | 2037/5465 |
| 近一月 | -3.52% | 2593/5421 |
| 近一季 | -8.71% | 3380/5231 |
| 近半年 | -5.03% | 2979/4920 |
| 近一年 | 2.03% | 2365/4394 |
| 近两年 | 56.20% | 1334/2954 |
| 近三年 | 15.00% | 1641/2253 |
| 成立以来 | 53.94% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.08% 2118/4961 |
17.53% 1464/5312 |
- - |
- - |
| 2025 | 22.17% 1992/4813 |
4.55% 914/3635 |
-1.73% 3258/4076 |
23.32% 1553/4524 |
-3.58% 3298/4813 |
| 2024 | 1.44% 2013/3463 |
-6.36% 2048/2808 |
-5.60% 1757/3014 |
15.88% 1603/3129 |
-0.97% 1556/3463 |
| 2023 | -19.01% 1839/2656 |
5.34% 795/2280 |
-7.31% 1833/2385 |
-10.48% 2002/2515 |
-7.34% 2118/2655 |
| 2022 | -27.41% 1478/2207 |
-19.94% 1509/1919 |
8.31% 372/2016 |
-15.88% 1362/2113 |
-0.48% 1616/2208 |
| 2021 | 8.49% 475/1822 |
-2.40% 635/1255 |
13.95% 273/1330 |
-5.09% 776/1466 |
2.78% 521/1822 |
| 2020 | 39.56% 330/1250 |
-7.09% 525/1028 |
23.87% 183/1067 |
7.83% 759/1164 |
12.45% 467/1184 |
| 2019 | 32.76% 443/1092 |
22.71% 570/754 |
-4.96% 449/804 |
3.70% 236/850 |
9.77% 196/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 南华中证杭州湾区ETF VS. 长安沪深300非周期A(740101) |